{
    "root": "34297547-1ef6-d244-e063-6394a90a55fa",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levofloxacin",
    "value": "20250502",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "LEVOFLOXACIN",
            "code": "6GNT3Y5LMF"
        }
    ],
    "indications": "levofloxacin fluoroquinolone antibacterial indicated adults ( 18 years age older ) infections caused designated , susceptible bacteria pediatric patients indicated ( 1 , 12.4 ) . • pneumonia : nosocomial ( 1.1 ) community acquired ( 1.2 , 1.3 ) • skin skin structure infections ( sssi ) : complicated ( 1.4 ) uncomplicated ( 1.5 ) • chronic bacterial prostatitis ( 1.6 ) • inhalational anthrax , post-exposure adult pediatric patients ( 1.7 ) • plague adult pediatric patients ( 1.8 ) • urinary tract infections ( uti ) : complicated ( 1.9 , 1.10 ) uncomplicated ( 1.12 ) • acute pyelonephritis ( 1.11 ) • acute bacterial exacerbation chronic bronchitis ( 1.13 ) • acute bacterial sinusitis ( 1.14 ) usage reduce development drug-resistant bacteria maintain effectiveness levofloxacin antibacterial drugs , levofloxacin used treat prevent infections proven strongly suspected caused bacteria ( 1.15 ) .",
    "contraindications": "• administer levofloxacin tablets pediatric patients weighing 30 kg greater ( 2.1 , 2.2 ) . • levofloxacin tablets administered pediatric patients weigh less 30 kg limitations available strengths . alternative formulations levofloxacin may considered pediatric patients weigh less 30 kg ( 2.2 ) . adult pediatric patients creatinine clearance greater equal 50 ml/minute ( 2.1 , 2.2 ) type infection dose every 24 hours duration ( days ) nosocomial pneumonia ( 1.1 ) 750 mg 7 14 community acquired pneumonia ( 1.2 ) 500 mg 7 14 community acquired pneumonia ( 1.3 ) 750 mg 5 complicated sssi ( 1.4 ) 750 mg 7 14 uncomplicated sssi ( 1.5 ) 500 mg 7 10 chronic bacterial prostatitis ( 1.6 ) 500 mg 28 inhalational anthrax ( post-exposure ) ( 1.7 ) adults pediatric patients 50 kg greater pediatric patients 30 kg less 50 kg ( 2.2 ) 500 mg 250 mg every 12 hours 60 60 plague ( 1.8 ) adults pediatric patients 50 kg greater pediatric patients 30 kg less 50 kg ( 2.2 ) 500 mg 250 mg every 12 hours 10 14 10 14 complicated uti ( 1.9 ) acute pyelonephritis ( 1.11 ) 750 mg 5 complicated uti ( 1.10 ) acute pyelonephritis ( 1.11 ) 250 mg 10 uncomplicated uti ( 1.12 ) 250 mg 3 acute bacterial exacerbation chronic bronchitis ( 1.13 ) 500 mg 7 acute bacterial sinusitis ( 1.14 ) 750 mg 5 500 mg 10 14 • adjust dose creatinine clearance less 50 ml/minute ( 2.3 , 8.6 , 12.3 )",
    "warningsAndPrecautions": "levofloxacin tablets usp , 750 mg white colored , capsule shaped , biconvex , film coated tablets debossed '18 ' one side ' ' side . supplied ndc : 70518-0968-00 ndc : 70518-0968-01 ndc : 70518-0968-02 ndc : 70518-0968-03 packaging : 30 1 blister pack packaging : 20 1 blister pack packaging : 7 1 bottle plastic packaging : 5 1 bottle plastic store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "levofloxacin tablets contraindicated persons known hypersensitivity levofloxacin , quinolone antibacterials [ ( 5.3 ) ] .",
    "indications_original": "Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated  ( 1 , 12.4 ). • Pneumonia: Nosocomial ( 1.1 ) and Community Acquired ( 1.2 , 1.3 ) • Skin and Skin Structure Infections (SSSI): Complicated ( 1.4 ) and Uncomplicated ( 1.5 ) • Chronic bacterial prostatitis ( 1.6 ) • Inhalational Anthrax, Post-Exposure  in adult and pediatric patients  ( 1.7 ) • Plague in adult and pediatric patients ( 1.8 ) • Urinary Tract Infections (UTI): Complicated ( 1.9 , 1.10 ) and Uncomplicated ( 1.12 ) • Acute Pyelonephritis ( 1.11 ) • Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.13 ) • Acute Bacterial Sinusitis ( 1.14 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.15 ).",
    "contraindications_original": "• Administer levofloxacin tablets to pediatric patients  weighing 30 kg and greater  only ( 2.1 , 2.2 ). • Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg ( 2.2 ). Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute (2.1, 2.2) Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia (1.1) 750 mg 7 to 14 Community Acquired Pneumonia (1.2) 500 mg 7 to 14 Community Acquired Pneumonia (1.3) 750 mg 5 Complicated SSSI (1.4) 750 mg 7 to 14 Uncomplicated SSSI (1.5) 500 mg 7 to 10 Chronic Bacterial Prostatitis (1.6) 500 mg 28 Inhalational Anthrax (Post-Exposure) (1.7) Adults and Pediatric Patients 50 kg or greater Pediatric Patients 30 kg to less than 50 kg (2.2) 500 mg 250 mg every 12 hours 60 60 Plague (1.8) Adults and Pediatric Patients 50 kg or greater Pediatric Patients 30 kg to less than 50 kg (2.2) 500 mg 250 mg every 12 hours 10 to 14 10 to 14 Complicated UTI (1.9) or Acute Pyelonephritis (1.11) 750 mg 5 Complicated UTI (1.10) or Acute Pyelonephritis (1.11) 250 mg 10 Uncomplicated UTI (1.12) 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (1.13) 500 mg 7 Acute Bacterial Sinusitis (1.14) 750 mg 5 500 mg 10 to 14 •  Adjust dose for creatinine clearance less than 50 mL/minute ( 2.3 , 8.6 , 12.3 )",
    "warningsAndPrecautions_original": "Levofloxacin Tablets USP, 750 mg are white colored, capsule shaped, biconvex, film coated tablets debossed with '18' on one side and 'I' on the other side. They are supplied in\n                  NDC: 70518-0968-00\n                  NDC: 70518-0968-01\n                  NDC: 70518-0968-02\n                  NDC: 70518-0968-03\n                  PACKAGING: 30 In 1 BLISTER PACK\n                  PACKAGING: 20 in 1 BLISTER PACK\n                  PACKAGING: 7 in 1 BOTTLE PLASTIC\n                  PACKAGING: 5 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials\n \n  [see Warnings and Precautions (\n  \n   5.3)]."
}